

bs-1529R**[Primary Antibody]****CD46 Rabbit pAb****Bioss**
ANTIBODIES

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn


400-901-9800

DATASHEET**Host:** Rabbit**Isotype:** IgG**Clonality:** Polyclonal**GeneID:** 4179**SWISS:** P15529**Target:** CD46**Immunogen:** KLH conjugated synthetic peptide derived from human CD46: 251-355/355. < Extracellular >**Purification:** affinity purified by Protein A**Concentration:** 1mg/ml**Storage:** 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.


Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: CD46 is one of the membrane complement regulatory proteins. CD46 possesses C3b-binding and factor I cofactor activities which play important roles in the regulation of the complement activation pathway. CD46 is widely distributed on blood cells, endothelial cells, epithelial cells and tumor cell lines. CD46 exists as many isoforms in a variety of tissues. The antigen has a broad distribution and is present on leukocytes, platelets, endothelial cells, epithelial cells and fibroblasts. It is strongly expressed on salivary gland ducts and kidney ducts, moderately on lymphocytes and endothelium, and weakly on interstitial tissues and muscle cells, but not on erythrocytes. It is expressed on thymocytes, B cells, monocytes, granulocytes, NK cells, platelets, epithelial and endothelial cells.**Applications:** WB (1:500-2000)**IHC-P** (1:100-500)**IHC-F** (1:100-500)**IF** (1:100-500)**Flow-Cyt** (1µg /test)**Reactivity:** Human, Mouse**Predicted MW.:** 43 kDa**Subcellular Location:** Cell membrane**VALIDATION IMAGES**


Sample: Lane 1: Mouse Placenta tissue lysates
 Lane 2: Mouse Lung tissue lysates Lane 3:
 Human K562 cell lysates Lane 4: Human HeLa
 cell lysates Lane 5: Human MOLT4 cell lysates
 Lane 6: Human MCF-7 cell lysates Lane 7: Human
 Daudi cell lysates Primary: Anti-CD46 (bs-1529R)
 at 1/1000 dilution Secondary: IRDye800CW Goat
 Anti-Rabbit IgG at 1/20000 dilution Predicted
 band size: 43 kDa Observed band size: 52 kDa



Paraformaldehyde-fixed, paraffin embedded
 (Human colon carcinoma); Antigen retrieval by
 boiling in sodium citrate buffer (pH6.0) for
 15min; Block endogenous peroxidase by 3%
 hydrogen peroxide for 20 minutes; Blocking
 buffer (normal goat serum) at 37°C for 30min;
 Antibody incubation with (CD46) Polyclonal
 Antibody, Unconjugated (bs-1529R) at 1:400
 overnight at 4°C, followed by operating
 according to SP Kit(Rabbit) (sp-0023)
 instructions and DAB staining.



Blank control: U937 (blue). Primary Antibody:
 Rabbit Anti- CD46 antibody(bs-1529R), Dilution:
 1µg in 100 µL 1X PBS containing 0.5% BSA;
 Isotype Control Antibody: Rabbit IgG(orange)
 ,used under the same conditions); Secondary
 Antibody: Goat anti-rabbit IgG-PE(white blue),
 Dilution: 1:200 in 1 X PBS containing 0.5% BSA.
 Protocol The cells were fixed with 2%
 paraformaldehyde (10 min). Primary antibody
 (bs-1529R, 1µg /1x10⁶ cells) were incubated for
 30 min on the ice, followed by 1 X PBS
 containing 0.5% BSA + 1.0% goat serum (15 min)
 to block non-specific protein-protein
 interactions. Then the Goat Anti-rabbit IgG/PE
 antibody was added into the blocking buffer
 mentioned above to react with the primary
 antibody at 1/200 dilution for 30 min on ice.
 Acquisition of 20,000 events was performed.



Blank control: 293T(blue). Primary Antibody: Rabbit Anti-CD46 antibody(bs-1529R), Dilution: 1 μ g in 100 μ L 1X PBS containing 0.5% BSA(green); Isotype Control Antibody: Rabbit IgG(orange), used under the same conditions); Secondary Antibody: Goat anti-rabbit IgG-PE(white blue), Dilution: 1:200 in 1 X PBS containing 0.5% BSA, protocol The cells were washed twice with phosphate-buffered saline (PBS).The cells were then incubated in 1 X PBS containing 0.5% BSA + 10% goat serum (15 min) to block non-specific protein-protein interactions followed by the antibody (bs-1529R, 1 μ g/1x10⁶ cells) for 30 min on ice. The secondary antibody used was Goat Anti-rabbit IgG/PE antibody at 1/200 dilution for 30 min on ice.Acquisition of 20,000 events was performed.

— SELECTED CITATIONS —

- **[IF=2.6]** Masahisa Hemmi. et al. Neutralizing monoclonal antibodies improve biodistribution of intravenously administered oncolytic adenovirus in human CD46-transgenic mice. PLOS ONE. 2025 Jun;20(6):e0326857 WB ;Mouse. 40561062